The Limitations of EQ-5D as a Clinical Outcome Assessment Tool
- PMID: 38466537
- DOI: 10.1007/s40271-024-00683-w
The Limitations of EQ-5D as a Clinical Outcome Assessment Tool
References
-
- Shaw C, Longworth L, Bennett B, McEntee-Richardson L, Shaw JW. A review of the use of EQ-5D for clinical outcome assessment in health technology assessment, regulatory claims, and published literature. The Patient Patient Centered Outcomes Res. 2023. https://doi.org/10.1007/s40271-023-00662-7 . - DOI
-
- Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and future. Appl Health Econ Health Policy. 2017;15(2):127–37. https://doi.org/10.1007/s40258-017-0310-5 . - DOI - PubMed - PMC
-
- NICE. Guide to the Methods of Technology Appraisal. 2004. https://assets.publishing.service.gov.uk/media/5a7a5acee5274a34770e6144/... . Accessed 10 Feb 2024.
-
- Kennedy-Martin M, Slaap B, Herdman M, van Reenen M, Kennedy-Martin T, Greiner W, et al. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ. 2020;21(8):1245–57. https://doi.org/10.1007/s10198-020-01195-8 . - DOI - PubMed - PMC
-
- Gnanasakthy A, Levy C, Norcross L, Doward L, Winnette R. A review of labeling based on patient-reported outcome endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017–2021). Value Health. 2023;26(6):893–901. https://doi.org/10.1016/j.jval.2023.01.017 . - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources